Abstract
Inflammation seems to be at the beginning of the majority of chronic diseases, and major efforts are dedicated to the development of anti-inflammatory drugs. Chronic inflammatory diseases, such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and asthma, are diseases that affect a large segment of our population. Recent evidence suggests that even metabolic diseases, such as type 2 diabetes, and certain cardiovascular diseases, could also be considered to have an inflammatory origin. However, a chronic disorder that in its initial and even more advanced stages is often not life-threatening, presents a challenge for therapeutic intervention: companies have to develop drugs that are efficacious, relatively free of side effects, and can be used effectively for a long time. The identification of suitable targets, thus, depends on better understanding of the signaling pathways involved in the initiation and maintenance of inflammation. The availability of target validation technology, such as targeted mutagenesis in mice, gene silencing mediated by small interfering RNA and protein expression profiling in this context is of utmost importance. Here, we will focus on the latter two technologies.
Keywords: Mitogen Activated Protein (MAP) Kinases, Phosphoinositide 3-Kinases, Syk-Family Kinases, siRNA transfection, Protein Arrays
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling
Volume: 6 Issue: 1
Author(s): Tatjana Clarissa Gust and Arne v. Bonin
Affiliation:
Keywords: Mitogen Activated Protein (MAP) Kinases, Phosphoinositide 3-Kinases, Syk-Family Kinases, siRNA transfection, Protein Arrays
Abstract: Inflammation seems to be at the beginning of the majority of chronic diseases, and major efforts are dedicated to the development of anti-inflammatory drugs. Chronic inflammatory diseases, such as psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and asthma, are diseases that affect a large segment of our population. Recent evidence suggests that even metabolic diseases, such as type 2 diabetes, and certain cardiovascular diseases, could also be considered to have an inflammatory origin. However, a chronic disorder that in its initial and even more advanced stages is often not life-threatening, presents a challenge for therapeutic intervention: companies have to develop drugs that are efficacious, relatively free of side effects, and can be used effectively for a long time. The identification of suitable targets, thus, depends on better understanding of the signaling pathways involved in the initiation and maintenance of inflammation. The availability of target validation technology, such as targeted mutagenesis in mice, gene silencing mediated by small interfering RNA and protein expression profiling in this context is of utmost importance. Here, we will focus on the latter two technologies.
Export Options
About this article
Cite this article as:
Clarissa Gust Tatjana and Bonin v. Arne, Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (1) . https://dx.doi.org/10.2174/187152307779939723
DOI https://dx.doi.org/10.2174/187152307779939723 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Current Concepts in the Understanding of Pain in the Rheumatic Diseases
Current Rheumatology Reviews The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry Alternative Aβ Immunotherapy Approaches for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Stem Cells in MDR-TB and XDR - TB
Current Respiratory Medicine Reviews Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Current Cancer Drug Targets Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology Successful Structure-Based Design of Recent p38 MAP Kinase Inhibitors
Current Topics in Medicinal Chemistry Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews Autoimmune Hepatitis After Long-Term Methotrexate Therapy for Rheumatoid Arthritis
Current Drug Safety Editorial: [Hot Topic: Keeping Track of an Expanding Subject - Recent Trends in Immunology and their Clinical Implications]
Current Pharmaceutical Design Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Physiologic Versus Diabetogenic Effects of Interleukin-1: A Question of Weight
Current Pharmaceutical Design Concept of Comprehensive Treatment for Osteoarthritis (OA)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design